Sagar Cements reports turnaround Q1 numbers
Revenue from operations increased 19.63% to Rs 670.66 crore in Q1 FY26 as against Rs 560.60 crore in Q1 FY25, supported by strong price hikes in the Southern market and various incentive schemes.
The company reported a pre-tax profit of Rs 23.90 crore in Q1 FY26 as compared with a pre-tax loss of Rs 47.55 crore recorded in the corresponding quarter last year.
Operating EBITDA surged 160.06% year-on-year to Rs 121.45 crore in Q1 FY26. EBITDA margin stood at 18% in Q1 FY26 as against 18% in Q1 FY25.
During the quarter, sales volume jumped 11.26% to 1,427,639 million tonnes (MT) from 1,127,902 MT recorded in Q1 FY25.
As of 30 June 2025, the company's net debt stood at Rs 1,374.24 crore.
Sreekanth Reddy, the joint managing director of the company, said, We have started the year on a strong note, as can be seen from our financials. Volumes for the quarter grew by 11% on a Y-o-Y basis, driven by pickup in government spending, the construction sector, and the housing sector. In addition to higher volumes, the quarterly performance was also aided by a better pricing environment. The combination of which resulted in revenue growth of 20% (Y-o-Y) for the quarter.
Our modernization plans at the Andhra Cements Dachepalli unit are progressing as per schedule. We are confident of achieving our target volume of approximately 6 MnT in FY26. The Board of one of the subsidiaries, Sagar Cements (M), has given approval to take up the expansion of cement grinding capacity from 1 MTPA to 1.5 MTPA and, as part of green energy initiatives, to establish a 6 MW solar power plant, involving a capex of around Rs 140 crore.
In conclusion, we believe our enhanced capacities position us strongly to capitalize on the growing demand from the infrastructure and real estate sectors in the coming years. Additionally, our continued focus on diversifying revenue streams and expanding our regional presence is expected to further strengthen the companys overall profitability profile.
Sagar Cements is engaged in the business of manufacturing and selling cement.
Shares of Sagar Cements fell 1.60% to Rs 265.05 on the BSE.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
27 minutes ago
- Hindustan Times
Lord's Mark Industries Ltd Prepares for BSE Market Entry, Eyes NSE Listing and Worldwide Business Expansion
Lord's Mark Industries Ltd, a prominent and rapidly growing Indian conglomerate with business interests spanning healthcare, diagnostics, renewable energy, and cutting-edge technology, is poised to make its mark on the capital markets with an upcoming listing on the Bombay Stock Exchange (BSE). This milestone move reflects the company's strategic ambition to elevate its presence, not just within India, but across global business landscapes. Lord's Mark Industries Ltd Prepares for BSE Market Entry This listing follows the company's recent National Company Law Tribunal (NCLT) clearance for the merger with Lord's Mark India Ltd (formerly Kratos Energy and Infrastructure Ltd) — a significant development that is reshaping the group's business trajectory. The merger is designed to unlock operational efficiencies, enabling greater resource optimisation, streamlined management, and robust expansion into new verticals. Beneficial Share Swap for Investors - As part of the merger structure, shareholders of Lord's Mark Industries Ltd will be entitled to a share swap ratio of 1:1.25. For every share held in Lord's Mark Industries Ltd, investors will receive 1.25 shares in the newly consolidated Lord's Mark India Ltd. This favourable ratio underscores the company's commitment to creating value for its shareholders and supports the vision of building a stronger, more dynamic corporate entity. Strong Global Investor Backing and Strategic Partnerships - The announcement of the BSE listing has also been accompanied by significant interest from international investors, demonstrating robust confidence in Lord's Mark Industries' diversified business approach, resilience, and forward-looking strategies. Notably, the company has received a high-value proposal for a global partnership concerning its Medtech product line—a flagship portfolio in the green energy segment. This partnership is poised to accelerate the company's international reach and solidify its standing as a key player in the renewable energy market. Capital Market Journey: BSE Launch, NSE on the Horizon - The BSE listing serves as the launchpad for Lord's Mark Industries' wider capital market journey. With eyes set on further growth, the company has initiated plans to pursue a listing on the National Stock Exchange (NSE) within the next six months. This dual-exchange presence is anticipated to boost stock liquidity, expand the investor base, and enhance visibility among both domestic and foreign institutional investors. The NSE listing will also offer better price discovery and increased access to capital — factors that are crucial for the company's future growth plans. To know more visit: Note to the Reader: This article is part of Hindustan Times' promotional consumer connect initiative and is independently created by the brand. Hindustan Times assumes no editorial responsibility for the content.
Mint
27 minutes ago
- Mint
Lord's Mark Industries Ltd Prepares for BSE Market Entry, Eyes NSE Listing and Worldwide Business Expansion
Lord's Mark Industries Ltd, a distinguished and rapidly developing Indian business group with diverse interests encompassing healthcare, diagnostics, sustainable energy, and innovative technology, is ready to establish its presence in the capital markets through an upcoming Bombay Stock Exchange (BSE) listing. This landmark decision reflects the corporation's strategic commitment to enhancing its presence across Indian and international business environments. The market entry follows the organisation's recent National Company Law Tribunal (NCLT) authorisation for the business combination with Lord's Mark India Ltd (formerly identified as Kratos Energy and Infrastructure Ltd), a crucial development that is reshaping the company's operational direction. The business combination is designed to generate operational efficiencies, enable superior resource management, streamline organisational oversight, and facilitate dynamic expansion into additional industry verticals. Within the business combination structure, Lord's Mark Industries Ltd shareholders will be granted a share conversion ratio of 1:1.25. For each existing share, investors will obtain 1.25 shares in the combined Lord's Mark India Ltd entity. This favourable conversion formula emphasises the company's commitment to generating enhanced value for shareholders while building a stronger and more dynamic business organisation. The BSE listing declaration has been met with substantial interest from worldwide investors, demonstrating solid confidence in Lord's Mark Industries' varied business model, market stability, and forward-thinking strategies. The company has obtained a significant partnership proposal regarding its Medtech business line, a flagship division within the sustainable energy sector. This partnership is positioned to accelerate the company's international expansion and establish its reputation as a major participant in the renewable energy marketplace. The BSE listing functions as the launching platform for Lord's Mark Industries' extended capital market journey. With growth objectives in focus, the company has established plans to secure National Stock Exchange (NSE) listing within the next six-month period. This multi-exchange presence is anticipated to increase stock trading activity, expand the investment community, and improve market visibility among both domestic and foreign institutional investors. The NSE listing will also provide enhanced price discovery mechanisms and increased capital availability, factors that are vital for the company's future development initiatives. To learn more visit: Note to the Reader: This article is part of Mint's promotional consumer connect initiative and is independently created by the brand. Mint assumes no editorial responsibility for the content.
&w=3840&q=100)
Business Standard
27 minutes ago
- Business Standard
Smallcap pharma stock hits 52-week low, slips 8% on Q1 loss. Do you own?
Hikal stock price today Shares of Hikal hit a 52-week low of ₹281.90, slipping 8 per cent on the BSE in Thursday's intra-day trade after the company posted a net loss of ₹22.4 crore in the June 2025 quarter (Q1FY26). The pharmaceutical company had reported a net profit of ₹5.1 crore in a year ago quarter (Q1FY25). The stock has corrected 39 per cent from its 52-week high level of ₹464.50, touched on December 2, 2024. At 02:29 PM; Hikal was trading 7 per cent lower at ₹285.50, as compared to 0.43 per cent decline in the BSE Sensex. Q1 results – Hikal For the April to June 2025 quarter (Q1FY26), Hikal posted a net loss of ₹22.4 crore, as against net profit of ₹5.1 crore in a year ago quarter (Q1FY25). Revenue from operations declined 6 per cent at ₹380.4 crore from ₹406.40 crore in a year ago quarter. Hikal's profitability remains vulnerable to volatility in raw material prices and the competitive pressures in the industry. The reduction in demand and adverse pricing pressure in recent times led to a reduction in its operating margin. While announcing the Q4 results on May 14, 2025, Hikal said FY25 has been marked by heightened macroeconomic uncertainty and geopolitical tensions, with trade disruptions - such as retaliatory tariffs in key markets such as the US and EU - exerting pressure on global supply chains and input costs. Amid this volatility, the management said the company is actively reshaping its business by diversifying product portfolio, forging deeper customer partnerships, and building end-to-end supply chain resilience. In the crop protection business, where margin pressures are rising, the company is focusing on capacity utilization and operational efficiency whilst aggressively building the future pipeline. ICRA's view on Hikal Hikal's operating profit margin (OPM) remains vulnerable to adverse movement in key raw material prices, which is also demonstrated by the volatility in its OPM in the recent past. Its profitability also remains exposed to volatility in foreign currency rates on account of its exports. This is partly mitigated by a natural hedge on account of Hikal's imports, ICRA said in April 2025 rating rationale. Hikal is involved in various regulatory actions/ litigations, including the ongoing legal proceedings related to the company having alleged involvement in a gas leak accident at Surat (Sachin GIDC area) in Gujarat. The National Green Tribunal (NGT) imposed a penalty (₹ 17.45 crore in October 2022) on Hikal on account of the alleged violation of environmental laws, which the company has contested legally before the Hon'ble Supreme Court, and the matter remains sub judice. Moreover, the Hon'ble Supreme Court has, vide its order dated April 8, 2024, stayed the recovery of the penalty imposed by NGT. The matter is currently pending before the Hon'ble Supreme Court of India which stayed the order passed by the National Green Tribunal, Principal Bench, New Delhi which had accepted the joint committee's reports, including recovery of compensation of ₹ 17.45 crore from the Holding Company for aforesaid non-compliance, Hikal said in Q1 note of accounts. About Hikal Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal's advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors.
